Clinical study of pressure induced corneal endothelial cell injury in acute angle closure glaucoma

Effects of different anterior chamber puncture schemes on corneal endothelial cells and the effect of anterior vitrectomy combined with drug hypotension on corneal endothelial cells

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052096

Enrollment

Unknown

Registered

2021-10-17

Start date

2022-02-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute primary angle closure glaucoma

Interventions

Sudden drop of intraocular pressure group 1:Traditional anterior chamber puncture

Sudden drop of intraocular pressure group 2:Novel anterior chamber puncture

Anterior vitrectomy decompression group:Anterior vitrectomy

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The initial intraocular pressure in patients with angle closure glaucoma complicated with cataract was >= 45 mmHg; 2. Local and drug treatment within 48 hours was ineffective. The drug treatment regimen was: 1% pilocarpine eye drops, once every 15 minutes; intravenous drip of 20% mannitol 250 ml, twice a day; 2% cataprolol eye drops twice a day; 1% brinzolamide eye drops 3 times/d.

Exclusion criteria

Exclusion criteria: 1. Patients who cannot tolerate anterior chamber puncture; 2. Elevated intraocular pressure glaucoma with corneal endothelial related diseases, such as pseudoexudative glaucoma, iris corneal endothelial syndrome, etc.; 3. Previous history of acute attack of angle closure glaucoma, grade IV above nuclear hardness, anterior chamber shallow puncture of anterior chamber puncture group, irreversible incarceration in the puncture site, no fluid release, diabetes, chronic angle closure glaucoma, ocular trauma, intraocular surgery history, and other congenital diseases such as keratoconus and corneal dystrophy; 4. Subjects participating in other drug trials or clinical trials of medical devices within 1 month; 5. Patients with mental disorders that hinder treatment and evaluation; 6. Lactating women or pregnant women; 7. Subjects considered unsuitable by the investigator to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Corneal endothelial cell density;Coefficient of variation of corneal endothelial cells;Intraocular pressure;	—

Secondary

Measure	Time frame
Anterior chamber exudation;Iris atrophy;Optic nerve thickness;Pupil size;Pupil shape;	—

Countries

China

Contacts

Public ContactBi Yanlong

Tongji Hospital Affiliated to Tongji University

biyanlong@tongji.edu.cn+86 13816261568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026